Key facts
- PERCEPTIVE ADVISORS LLC filed SCHEDULE 13G/A for Amylyx Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (AMLX).
- Disclosed ownership: 7.5%.
- Date of event: 31 Mar 2026.
PERCEPTIVE ADVISORS LLC - 31 Mar 2026 SCHEDULE 13G/A Report for Amylyx Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (AMLX)
- Filing Manager
- PERCEPTIVE ADVISORS LLC
- Reporting Manager
- Perceptive Advisors LLC
- Symbol
- AMLX
- Shares outstanding
- 110,465,093 shares
- Disclosed Ownership
- 8,284,882 shares
- Ownership
- 7.5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 May 2026, 16:00:03 UTC
- Date of event
- 31 Mar 2026
- Previous filing
- 14 Nov 2025
- SEC
- View on sec.gov
Key filing fact
PERCEPTIVE ADVISORS LLC disclosed 7.5% ownership in Amylyx Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (AMLX) on 31 Mar 2026.
Change
- Previous schedule filing date: 14 Nov 2025.
- Current filing was accepted on 15 May 2026, 16:00.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (3)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Perceptive Advisors LLC | 7.5% | 8,284,882 | 0 | 8,284,882 | /s/ Joseph Edelman | Joseph Edelman, Managing Member | |
| Joseph Edelman | 7.5% | 8,284,882 | 0 | 8,284,882 | /s/ Joseph Edelman | Joseph Edelman | |
| Perceptive Life Sciences Master Fund, Ltd. | 7.5% | 8,284,882 | 0 | 8,284,882 | /s/ Joseph Edelman | Joseph Edelman, Managing Member |
CIK / CUSIP context first